drugset / Trial / NCT02964689
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
NaSingle-groupOpen-labelTreatment
Summary
The aim is to determine the recommended phase 2 dose (RP2D) of binimetinib in combination with pemetrexed and cisplatin, and to demonstrate that the combination is feasible and has preliminary activity in previously untreated patients with advanced NSCLC and documented KRAS mutations.
Timeline
- Start
- 2017-04-12
- Primary completion
- 2021-07-02
- Completion
- 2021-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |